Unzyme Laboratories and NHS England have announced a pilot program to evaluate the integration of select enhancement technologies within the National Health Service framework. The two-year initiative will operate at five NHS trusts and aims to develop models for public healthcare provision of human enhancement.
Program Objectives
The pilot program seeks to answer critical questions about enhancement delivery in public healthcare:
- Clinical pathways: How should enhancement services integrate with existing care models?
- Patient selection: What criteria should guide NHS-funded enhancement access?
- Training requirements: How can NHS clinicians be prepared to deliver enhancement care?
- Cost-effectiveness: What is the value proposition of enhancement versus traditional treatments?
- Equity considerations: How can equitable access be ensured across diverse populations?
Participating Technologies
The pilot will include a limited subset of our enhancement portfolio, specifically:
- OptiLens Pro: For patients with severe, treatment-resistant visual impairment
- ExoFrame components: For patients with specific mobility limitations
- NeuroLink Interface: For patients with certain neurological conditions
These technologies were selected based on clear medical indication, established safety profiles, and potential to demonstrate value within the NHS context.
Participating Trusts
Five NHS trusts across England will participate:
- Guy’s and St Thomas’ NHS Foundation Trust (London)
- Manchester University NHS Foundation Trust
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- University Hospitals Birmingham NHS Foundation Trust
- Cambridge University Hospitals NHS Foundation Trust
These trusts were selected for their expertise in relevant clinical areas and research capabilities.
Statement from NHS England
“We have a responsibility to evaluate emerging technologies that may benefit patients,” stated the NHS National Medical Director. “This carefully designed pilot will generate evidence to inform future decisions about enhancement technology within the NHS.”
Statement from Unzyme Laboratories
“Healthcare systems worldwide are grappling with how to approach human enhancement,” noted Dr. Plunkett. “We’re honored to work with the NHS to develop thoughtful, evidence-based approaches that could serve as models globally.”
Patient Information
Patients interested in pilot participation should speak with their NHS specialists. Eligibility is determined by clinical criteria established for the program; direct enrollment through Unzyme Laboratories is not available for this initiative.
For more information about our healthcare applications, visit our healthcare page.